Long-term Immunosuppression With Anti-CD25 Monoclonal Antibodies in Heart Transplant Patients With Chronic Kidney Disease

The use of long-term anti-CD25 MAb therapy as a potential replacement for CNI- and rapamycin-based immunosuppression is feasible. It is crucial that rejection surveillance be intensified. A randomized, controlled trial is required to confirm the benefits and safety of this strategy.